<DOC>
	<DOCNO>NCT00003376</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . It yet know four-drug combination chemotherapy effective two-drug combination chemotherapy treat advanced cancer urothelium . PURPOSE : Randomized phase III trial compare effectiveness four-drug combination chemotherapy two-drug combination chemotherapy treat patient advanced cancer urothelium .</brief_summary>
	<brief_title>Two-Drug Combination Chemotherapy Compared With Four-Drug Combination Chemotherapy Treating Patients With Advanced Cancer Urothelium</brief_title>
	<detailed_description>OBJECTIVES : I . Compare objective response rate , duration remission , overall survival , quality life patient progress regional metastatic transitional cell carcinoma ( mixed histology component transitional cell carcinoma ) urothelium treat methotrexate , vinblastine , doxorubicin , cisplatin v carboplatin paclitaxel . II . Compare relative toxic effect treatment regimens patient population . OUTLINE : This randomize , multicenter study . Patients randomize 1 2 treatment arm . Arm I : Patients receive methotrexate IV day 1 , 15 , 22 ; vinblastine IV day 2 , 15 , 22 ; cisplatin IV 2 hour doxorubicin IV day 2 . Treatment repeat every 28 day total 6 course absence unacceptable toxicity disease progression . Arm II : Patients receive paclitaxel IV 3 hour immediately follow carboplatin IV 30 minute . Treatment repeat every 21 day total 6 course absence unacceptable toxicity disease progression . Quality life assess treatment , course 2 4 , 4 week last course , 10 month . Patients follow every 3 month 1 year every 6 month disease progression . PROJECTED ACCRUAL : A total 330 patient accrue study within 3.3 year .</detailed_description>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Urethral Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Transitional Cell</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Ureteral Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm transitional cell carcinoma urothelium ( renal pelvis , ureter , bladder , urethra ) mixed histology contain component transitional cell carcinoma urothelium manifestation progress regional metastatic cancer Clinically unsuspected organconfined prostate cancer find cystoprostatectomy allow Evaluable measurable disease No significant pericardial pleural effusion edema No significant ascites No CNS metastases PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : Granulocyte count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : AST great 2 time upper limit normal Bilirubin great 1.5 mg/dL Renal : Creatinine great 1.7 mg/dL Cardiovascular : No history severe cardiovascular disease ( American Heart Association class III IV ) , uncontrolled congestive heart failure , cardiac dysrhythmias Other : Prior malignancy allow curatively treated evidence recurrence No active infection require parenteral antibiotic Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : No prior systemic biologic response modifier therapy No concurrent filgrastim ( GCSF ) within 24 hour prior study chemotherapy administration Chemotherapy : No prior systemic chemotherapy Endocrine therapy : Not specify Radiotherapy : No prior pelvic radiotherapy component bladdersparing therapy adjuvant locally advance disease positive margin No concurrent local radiotherapy pain control lifethreatening situation Surgery : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>stage III bladder cancer</keyword>
	<keyword>stage IV bladder cancer</keyword>
	<keyword>transitional cell carcinoma bladder</keyword>
	<keyword>anterior urethral cancer</keyword>
	<keyword>posterior urethral cancer</keyword>
	<keyword>urethral cancer associate invasive bladder cancer</keyword>
	<keyword>metastatic transitional cell cancer renal pelvis ureter</keyword>
	<keyword>regional transitional cell cancer renal pelvis ureter</keyword>
</DOC>